Thus, beyond recommendations favoring monoclonal antibodies against TNF in patients with a history of recurrent uveitis or active IBD and preferring an IL-17i in patients with significant psoriasis, the choice of therapeutic agent is empirical [44,54,61]. The gene discussed is TNF; the disease is uveitis.